Enhanced γ-globin reactivation and sickle cell correction through a repressor-to- activator motif switch in the HBG1/2 promoters

This study demonstrates that replacing the BCL11A repressor binding site with a TAL1:GATA1 activator motif in the HBG1/2 promoters, particularly via CRISPR/Cas9-mediated homology-directed repair combined with NHEJ/alt-EJ inhibition, effectively reactivates fetal hemoglobin and corrects the sickle cell phenotype in patient-derived hematopoietic stem cells.

The Gist

The Big Picture: Fixing a Broken Factory

Imagine your body is a massive factory that produces red blood cells. These cells carry oxygen, like delivery trucks. In people with Sickle Cell Disease, there is a defect in the blueprints for these trucks. The trucks are shaped like sickles (crescent moons) instead of smooth circles. They get stuck, clog the roads (blood vessels), and cause pain and damage.

For a long time, doctors have known a secret: if you can get the factory to produce Fetal Hemoglobin (the "baby version" of the truck), it works perfectly and fixes the problem. The problem is, the factory has a "switch" that turns off the baby trucks once you are born.

This paper is about finding a way to jam that switch and install a super-charged engine to keep the baby trucks running forever.

---

The Problem: The "Off" Switch

Inside the DNA of every cell, there is a specific section called the HBG promoter. Think of this as the control panel for the baby truck factory.

1. The Bad Guy (BCL11A): There is a protein called BCL11A that acts like a security guard. It sits on the control panel and says, "Stop! No baby trucks allowed!"
2. The Goal: The scientists wanted to kick that security guard out of the building and replace his spot with a "Super On" button that screams, "Make more baby trucks!"

The Experiment: Two Different Tools

The team tried two different "tools" to make this repair in the DNA.

Tool 1: The "Prime Editor" (The Precision Surgeon)

They first tried a high-tech tool called Prime Editing.

• The Analogy: Imagine a surgeon with a tiny scalpel and a needle. They cut the DNA, write a new message on a piece of paper (the new "Super On" button), and try to sew it in.
• The Result: It worked okay in test cells (K562), but when they tried it on real patient stem cells, it was like trying to thread a needle in the dark. The tool was too slow and clumsy. It often made messy cuts or couldn't insert the new message cleanly. It was too "gentle" for the job.

Tool 2: The "CRISPR-HDR" Strategy (The Demolition Crew with a Blueprint)

Since the surgeon was struggling, they switched to a more aggressive but precise method: CRISPR-Cas9 with a DNA donor.

• The Analogy: Imagine a demolition crew (CRISPR) that blows a hole in the wall where the security guard is standing. But instead of just leaving a hole, they immediately bring in a construction crew with a blueprint (a DNA template) to build a brand new, reinforced "Super On" button right in that hole.
• The Secret Sauce: To make sure the construction crew didn't accidentally leave a messy pile of rubble (which happens when cells try to fix holes on their own), the scientists used special "inhibitors." Think of these as traffic cops that stop the messy repair crews (NHEJ and alt-EJ pathways) and force the cell to use the clean blueprint instead.

The Breakthrough

The second method (CRISPR-HDR) was a huge success.

1. It worked better: It installed the new "Super On" button much more frequently than the Prime Editor.
2. It was cleaner: It created fewer messy errors (mutations) in the DNA.
3. The Result: When they grew red blood cells from these edited patient stem cells, the cells were full of healthy Fetal Hemoglobin.
4. The Sickling Test: When they put these new cells in a low-oxygen environment (simulating a stressful situation), they stayed round and healthy. The "sickle" shape disappeared.

Why This Matters

• Better than just "turning off" the guard: Previous treatments just kicked the security guard (BCL11A) out. This study did that and installed a "Super On" button (TAL1:GATA1) in his place. It's like not just firing the guard, but hiring a cheerleader to keep the factory running at 100%.
• Safety: The cells didn't lose their ability to grow or turn into blood cells. They remained healthy.
• The Future: This suggests that for patients with Sickle Cell Disease, we might be able to edit their own stem cells, put them back in their bodies, and cure the disease by making their blood cells produce the healthy "baby" version of hemoglobin forever.

Summary in One Sentence

The scientists found that using a "demolition crew with a blueprint" (CRISPR-HDR) is much better at installing a permanent "Super On" switch for healthy blood cells than a "precision surgeon" (Prime Editing), offering a promising new path to curing Sickle Cell Disease.

Technical Summary

1. Problem Statement

Sickle Cell Disease (SCD) and $\beta$-thalassemia are severe $\beta$-hemoglobinopathies caused by mutations in the adult $\beta$-globin gene (HBB). A promising therapeutic strategy involves reactivating the expression of fetal hemoglobin ($\gamma$-globin, encoded by HBG1/2), which compensates for defective adult hemoglobin and prevents red blood cell sickling.

• Current Limitations: Existing CRISPR-Cas9 therapies (e.g., exagamglogene autotemcel) primarily target the BCL11A erythroid enhancer to disrupt repression. While effective, this approach shows variable efficacy, can impact erythropoiesis, and relies solely on disrupting a repressor binding site (BS).
• The Gap: There is a need for strategies that not only disrupt repressors (like BCL11A) but also actively recruit transcriptional activators to maximize $\gamma$-globin expression. Furthermore, current genome editing tools often struggle to precisely insert large DNA sequences (like composite motifs) into primary hematopoietic stem/progenitor cells (HSPCs) without generating unwanted indels or large deletions.

2. Methodology

The authors developed and compared two distinct genome editing strategies to replace the BCL11A repressor binding site in the HBG1/2 promoters with a composite TAL1:GATA1 motif (an 18-bp sequence recognized by potent erythroid activators).

A. Prime Editing (PEn) Strategy

• Tool: Used PEnmax (Prime Editor with a Cas9 nuclease fused to reverse transcriptase, rather than a nickase) to facilitate the insertion of the 18-bp TAL1:GATA1 motif.
• Design: Designed pegRNAs targeting the BCL11A BS (-115 region) and LRF BS (-200 region). The pegRNAs included a reverse transcription template (RTT) containing the motif and a homology tail.
• Optimization:
  • Tested different pegRNA lengths (short vs. long homology tails).
  • Compared delivery methods: mRNA transfection vs. Ribonucleoprotein (RNP) complexes.
  • Applied DNA repair inhibitors: DNA-PK inhibitor (AZD7648) to block Non-Homologous End Joining (NHEJ) and Pol$\theta$ inhibitor (ART558) to block Alternative End Joining (alt-EJ/MMEJ).
• PRINS: Tested "Primed INSertions" using springRNAs to promote insertion via NHEJ.

B. CRISPR/Cas9-HDR Strategy

• Tool: Used standard Cas9 nuclease to create a double-strand break (DSB) at the -115 BCL11A BS.
• Template: Provided a single-stranded oligodeoxynucleotide (ssODN) donor containing the TAL1:GATA1 motif flanked by homology arms.
• Optimization:
  • Screened various ssODN designs (different homology arm lengths and strand orientations).
  • Applied the same dual inhibition strategy (DNA-PKi + Pol$\theta$i) to suppress NHEJ/alt-EJ and favor Homology-Directed Repair (HDR).

C. Biological Models

• Cell Lines: K562 erythroleukemia cells for initial screening and optimization.
• Primary Cells: CD34+ HSPCs derived from SCD patients.
• Differentiation: Edited HSPCs were differentiated into mature Red Blood Cells (RBCs) in liquid culture and Colony-Forming Unit (CFC) assays.
• Analysis: Used Next-Generation Sequencing (NGS), ddPCR (for 4.9-kb deletions), RT-qPCR, HPLC, and Flow Cytometry to assess editing efficiency, $\gamma$-globin expression, and sickling phenotypes.

3. Key Contributions

1. Novel "Repressor-to-Activator" Switch: Demonstrated that replacing a repressor binding site with a composite activator motif (TAL1:GATA1) yields higher $\gamma$-globin expression than simple disruption of the repressor site.
2. Evaluation of Prime Editing for Insertions: Showed that while PEnmax outperforms standard Prime Editors (PE2max) in K562 cells, it remains inefficient in primary HSPCs for inserting long sequences, often resulting in high rates of indels and large genomic deletions.
3. Optimization of HDR in HSPCs: Established that Cas9-HDR, when combined with dual inhibition of NHEJ and alt-EJ pathways, achieves superior precise editing efficiency in primary SCD HSPCs compared to Prime Editing.
4. Safety and Efficacy Validation: Confirmed that the HDR strategy preserves clonogenicity, does not impair erythroid differentiation, and significantly reduces RBC sickling.

4. Key Results

In K562 Cells (Optimization Phase)

• PEn vs. PE: PEnmax generated ~45% total editing events at the -115 site, with ~19% being precise edits. However, it also induced significant indels and 4.9-kb deletions (loss of HBG2).
• Inhibitors: Dual inhibition (2i) significantly improved product purity for both PEn and Cas9-HDR by reducing indels.
• Cas9-HDR Superiority: Cas9-HDR with ssODN and 2i treatment achieved ~93% total editing efficiency with only ~3.4% indels and high precise edit rates, outperforming the best PEn conditions.

In Primary SCD HSPCs

• Prime Editing Limitations: PEn strategies yielded low editing efficiency in primary cells (approx. 1.1% precise edits), with indels often exceeding precise edits.
• HDR Success: The Cas9-HDR strategy with 2i treatment achieved ~17% precise edits in liquid cultures, significantly higher than PEn.
• Expression Levels:
  • Edited cells showed robust $\gamma$-globin reactivation at both mRNA and protein levels.
  • Clonal Analysis: Single-cell clones with the precise TAL1:GATA1 insertion showed significantly higher $\gamma$-globin expression ($R^2=0.68$ correlation) compared to clones with only indels disrupting BCL11A.
  • The "Repressor-to-Activator" switch resulted in higher HbF levels than strategies that only disrupted the BCL11A site.
• Phenotypic Correction:
  • Edited RBCs showed a marked decrease in sickling under hypoxic conditions.
  • The Cas9-HDR approach reduced sickling more effectively than Cas9-only disruption.
• Safety: No off-target indels were detected at the major predicted off-target site. Erythroid differentiation and enucleation rates were comparable to controls.

5. Significance

• Therapeutic Advancement: This study provides a proof-of-concept that combining repressor disruption with activator recruitment is a superior strategy for treating SCD, potentially requiring fewer edited cells to achieve a therapeutic benefit due to the "selective advantage" of the activated promoter.
• Methodological Insight: It highlights the current limitations of Prime Editing for large insertions in primary stem cells and validates Cas9-HDR with repair pathway modulation as a more robust and efficient alternative for precise motif replacement in a clinical setting.
• Clinical Relevance: The strategy preserves stem cell function and corrects the sickling phenotype, offering a promising avenue for next-generation gene therapies that could potentially outperform current FDA-approved CRISPR treatments (like Casgevy) in terms of HbF induction magnitude.

Conclusion: The authors successfully engineered a "repressor-to-activator" switch in the HBG1/2 promoters. While Prime Editing was explored, the study concludes that Cas9-HDR with NHEJ/alt-EJ inhibition is the most effective method to install this therapeutic motif in primary SCD HSPCs, leading to superior $\gamma$-globin reactivation and sickle cell correction.